title: Comorbid personality disorder and treatment use in a community sample of youths: a 20-year follow-up.
abstract: OBJECTIVE
  The impact of comorbid personality disorder (PD) on subsequent treatment and psychotropic drug use was examined in a representative sample of over 700 individuals.
  
  
  METHODS
  Axis I disorders and PD were assessed by self- and mother-report at mean ages 13 and 22 years, and by self-report at mean age 33. Mothers reported treatment use by participants before mean age 33; participants reported treatment and psychotropic drug use at mean age 33.
  
  
  RESULTS
  Individuals with multiple axis I disorders without PD, axis I disorder-PD comorbidity, and single disorders were compared simultaneously to individuals not diagnosed. Overall, odds of subsequent and past year treatment or psychotropic drug use or both were highest when PD co-occurred with a mood, an anxiety, a disruptive, or a substance use disorder.
  
  
  CONCLUSIONS
  Co-occurring personality pathology may contribute to elevated mental health service use, including use of psychotropic drugs, among young adults in the community.
authors.affiliation: Department of Psychiatry, Columbia University, New York, NY, USA. sk57@columbia.edu
authors.forename: S
authors.initials: S
authors.lastname: Kasen
authors.forename: P
authors.initials: P
authors.lastname: Cohen
authors.forename: A E
authors.initials: AE
authors.lastname: Skodol
authors.forename: M B
authors.initials: MB
authors.lastname: First
authors.forename: J G
authors.initials: JG
authors.lastname: Johnson
authors.forename: J S
authors.initials: JS
authors.lastname: Brook
authors.forename: J M
authors.initials: JM
authors.lastname: Oldham
mesh_terms: D000293:Adolescent; D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D015331:Cohort Studies; D003156:Community Mental Health Services / Q000706:statistics & numerical data*; D015897:Comorbidity; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D019964:Mood Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D009518:New York; D016017:Odds Ratio; D010554:Personality Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D011619:Psychotropic Drugs / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D014600:Utilization Review / Q000706:statistics & numerical data
chemical_list: D011619:Psychotropic Drugs